- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01171950
CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients
June 23, 2022 updated by: Abbott Medical Devices
CentriMag Ventricular Assist System (VAS): Treatment of Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients
The purpose of the study is to evaluate the safety and effectiveness of the CentriMag ventricular assist system to help pediatric patients who have experienced heart failure during surgery and cannot be removed from cardiac bypass.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 16 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 5 years to 16 years, inclusive
- Inability to wean from cardiopulmonary bypass (CPB)
Exclusion Criteria:
- Body weight < 20 kg
- Severe aortic insufficiency
- Unrestricted intra-cardiac communications (i.e. large VSD)
- Pulmonary vascular resistance index (PVRI) > 10 IU
- Presence of DIC
- On hemodialysis (excluding hemofiltration)
- Contraindications to systemic anticoagulation
- Active systemic infection unresponsive to antibiotics
- Unresolved malignancy
- On other investigational VAS
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: All Patients
All patients meeting the patient selection criteria will be treated with the CentriMag device.
|
All patients will be treated with the CentriMag device for up to 30 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival
Time Frame: 30 days after device removal, or, induction of anesthesia for implant of a long-term device or heart transplant
|
In patients who recover and do not go on to transplantation or a long-term device: • Survival 30 days after removal of the CentriMag VAS or to discharge, whichever is longer. In patients who do not recover: • Ability to be removed from the CentriMag VAS and survive to induction of anesthesia for implantation of a long-term device or heart transplantation. |
30 days after device removal, or, induction of anesthesia for implant of a long-term device or heart transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of end-organ function
Time Frame: 30 days after device removal, or, to induction of anesthesia for implant of a long-term device or heart transplant
|
Improvements in measures of end-organ function
|
30 days after device removal, or, to induction of anesthesia for implant of a long-term device or heart transplant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Pooja Chatterjee, Thoratec Corporation/Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (ANTICIPATED)
December 1, 2012
Study Completion (ANTICIPATED)
December 1, 2012
Study Registration Dates
First Submitted
July 27, 2010
First Submitted That Met QC Criteria
July 27, 2010
First Posted (ESTIMATE)
July 29, 2010
Study Record Updates
Last Update Posted (ACTUAL)
June 24, 2022
Last Update Submitted That Met QC Criteria
June 23, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PED-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
University of Health Sciences LahoreRecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, SystolicPakistan
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Lakeland Regional Health Systems, Inc.RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IVUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Eli Lilly and CompanyNot yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, SystolicUnited States, Japan
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
Clinical Trials on CentriMag Ventricular Assist System
-
Abbott Medical DevicesThoratec CorporationCompletedHeart FailureUnited States
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Shenzhen Core Medical Technology CO.,LTD.Not yet recruiting
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Shenzhen Core Medical Technology CO.,LTD.Completed
-
Abbott Medical DevicesThoratec Corporation; KCRI; Center for Life Sciences; EmergoCompletedAdvanced Refractory Left Ventricular Heart FailureGermany, Australia, Austria, Canada, Czechia, Kazakhstan
-
Shenzhen Core Medical Technology CO.,LTD.RecruitingCardiogenic ShockChina
-
Shenzhen Core Medical Technology CO.,LTD.Recruiting
-
Fujian Medical UniversityRecruiting